This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.
Medscape Medical News